We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 25, 2022

Pembrolizumab Plus Docetaxel and Prednisone in Patients With mCRPC

European Urology


Additional Info

European Urology
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study
Eur Urol 2022 Apr 06;[EPub Ahead of Print], EY Yu, MP Kolinsky, WR Berry, M Retz, L Mourey, JM Piulats, LJ Appleman, E Romano, G Gravis, H Gurney, M Bögemann, U Emmenegger, AM Joshua, M Linch, S Sridhar, HJ Conter, B Laguerre, C Massard, XT Li, C Schloss, CH Poehlein, JS de Bono

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading